HUE025504T2 - Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk - Google Patents

Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk Download PDF

Info

Publication number
HUE025504T2
HUE025504T2 HUE13198224A HUE13198224A HUE025504T2 HU E025504 T2 HUE025504 T2 HU E025504T2 HU E13198224 A HUE13198224 A HU E13198224A HU E13198224 A HUE13198224 A HU E13198224A HU E025504 T2 HUE025504 T2 HU E025504T2
Authority
HU
Hungary
Prior art keywords
mmol
compound
stirred
added
mixture
Prior art date
Application number
HUE13198224A
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE025504(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of HUE025504T2 publication Critical patent/HUE025504T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Claims (7)

  1. S*akvd»!sr:ä igénypontok ΐ. Legalább egyf afeövetkezők fcdzâî válásaiéit tegjíSföi:
    ë&'wgy legalább egy gyogyszérészeiibg eifogadbsíó sója.
  2. 2. Az j. igé8V|50Hí szerííitl legalább egy vegyíílel, aœ«ly a követelők klsall válasübott:
    és/'vagy legalább egy gyógyszereszetíieg el fogadható sója
  3. 3. Az 1. igénypont szerinti: vegyület. amely a
    ésóvagy legalább egy gyógyszerészetíleg elfogadható sója,
  4. 4. M I, igéöyjíOHí: iménti vágyóié!, amely a
  5. 5. Kásaftsaés^ amely tártál tnaz legalább egy, az 1-3, Igénypontok bármelyike: szermíi vegyúkM és/yagy legalább egy gyógyszerészeb leg elfogadható sóját, és legalább egy gyógyszsrészsííieg elfogadható hordozót. b. Legalább egy, az 1-3, igénypontok bármelyike szerinti vagyaiét ésévagy legalább egy gyógyszefoszetllsg elfogadható sója terápiában történő alkalmazásra.
  6. 7. Legalább egy, m 1-3, igénypontok bármelyike szermíi vegyidet ésfoagy legalább egy gyógyszerészetitsg elfogadható sója rák kezelésébe« történő -alkalmazásra.
    6. Legalább egy, az 1-3, igénypontok bármelyike szerinti vegyidet és/vagy legalább egy. gyógyszerészdlieg elfogadható sója rak kezelésében történő alkalmazásra a 7. igénypont szermi,; ahol a rák a kővetkezők közlrl választóit: töbörák, lej- és nyafci óik, koforekíáljs rak, kasttyálmirigyrák, vastagbéirák, emíSrák, petófoszekrák, prosztatarák, gyomorrait, veserák, májrák, agyi rák, esonirák és; leukémia.
  7. 9. Legalább egy, az 1-3, Igénypontok bármelyike szerinti vegyidet és/vagy legalább egy gyógyszerészei!leg elfogadható sáp rák kezelésében történő alkalmazásra a 7. igénypont szériát, alsói a vegyíifeiet egyóiíeseo adagoljak egy asstmeoplaszókas szerrel.
HUE13198224A 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk HUE025504T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31

Publications (1)

Publication Number Publication Date
HUE025504T2 true HUE025504T2 (hu) 2016-02-29

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE20199091A HUE059696T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
HUE19151824A HUE052828T2 (hu) 2009-12-31 2010-12-30 Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható
HUE13198224A HUE025504T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE20199091A HUE059696T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
HUE19151824A HUE052828T2 (hu) 2009-12-31 2010-12-30 Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható

Country Status (38)

Country Link
US (7) US8987269B2 (hu)
EP (5) EP2519524A4 (hu)
JP (5) JP5337313B2 (hu)
KR (3) KR101905350B1 (hu)
CN (3) CN106432225B (hu)
AU (2) AU2010338712B2 (hu)
BR (1) BR112012016129B1 (hu)
CA (1) CA2785749C (hu)
CL (1) CL2012001752A1 (hu)
CO (1) CO6612235A2 (hu)
CU (1) CU24167B1 (hu)
CY (2) CY1118250T1 (hu)
DK (3) DK3795573T3 (hu)
DO (1) DOP2012000188A (hu)
EA (2) EA025466B1 (hu)
EC (1) ECSP12012011A (hu)
ES (4) ES2927146T3 (hu)
GT (1) GT201200220A (hu)
HK (2) HK1194071A1 (hu)
HR (3) HRP20221090T1 (hu)
HU (3) HUE059696T2 (hu)
IL (2) IL220433B (hu)
LT (1) LT3795573T (hu)
ME (1) ME02211B (hu)
MX (1) MX336996B (hu)
MY (1) MY179933A (hu)
NI (1) NI201200118A (hu)
NZ (1) NZ601128A (hu)
PE (3) PE20160588A1 (hu)
PL (3) PL2719699T3 (hu)
PT (3) PT3511330T (hu)
RS (3) RS61281B1 (hu)
SG (1) SG181781A1 (hu)
SI (2) SI3511330T1 (hu)
SM (1) SMT201500213B (hu)
UA (1) UA107822C2 (hu)
WO (1) WO2011079804A1 (hu)
ZA (1) ZA201205730B (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2519524A4 (en) * 2009-12-31 2013-07-03 Hutchison Medipharma Ltd CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
KR20140144726A (ko) * 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
CN104903320B (zh) 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
EP3053923B1 (en) * 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
PL3087070T3 (pl) * 2013-12-26 2018-03-30 Ignyta, Inc. Pochodne pirazolo[1,5-a]pirydyny i sposoby ich zastosowania
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN109369656B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
US20220048904A1 (en) 2018-09-11 2022-02-17 Astrazeneca Ab Improved Method for the Manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN113454080A (zh) * 2018-10-30 2021-09-28 修复治疗公司 化合物、药物组合物和制备化合物的方法以及其使用方法
KR20210111779A (ko) 2018-12-14 2021-09-13 베타 파마, 인크. C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
CN116209754A (zh) * 2020-09-28 2023-06-02 科德克希思公司 用于合成手性胺的工程化生物催化剂及方法
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
JP2024501691A (ja) 2021-01-08 2024-01-15 アビオン インク． トリアゾロピラジン誘導体化合物を有効成分とする薬学的組成物のタブレット錠の製造方法
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
MX2007001127A (es) 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
BRPI0514327A (pt) 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc compostos triazolopiridina
DK1853602T3 (da) 2005-02-16 2010-09-20 Astrazeneca Ab Kemiske forbindelser
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
NZ575548A (en) 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
EP2081937B1 (en) * 2006-10-23 2012-09-12 SGX Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
WO2008064157A1 (en) 2006-11-22 2008-05-29 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2683398A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
KR20100128305A (ko) 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
ES2376404T3 (es) 2008-05-22 2012-03-13 Amgen Inc. Heterociclos como inhibidores de proteínas cinasas.
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
AU2010283806A1 (en) * 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
EP2519524A4 (en) * 2009-12-31 2013-07-03 Hutchison Medipharma Ltd CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
SMT201500213B (it) 2015-10-30
BR112012016129A2 (pt) 2016-05-31
CA2785749C (en) 2017-11-28
KR20120125261A (ko) 2012-11-14
PL3511330T3 (pl) 2021-04-19
EA030141B1 (ru) 2018-06-29
PE20130375A1 (es) 2013-04-10
UA107822C2 (en) 2015-02-25
MY179933A (en) 2020-11-19
PT3511330T (pt) 2020-12-24
ES2927146T3 (es) 2022-11-02
CY1118250T1 (el) 2017-06-28
JP6194046B2 (ja) 2017-09-06
PL2719699T3 (pl) 2016-01-29
ME02211B (me) 2016-02-20
US10512645B2 (en) 2019-12-24
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
JP6647434B2 (ja) 2020-02-14
CO6612235A2 (es) 2013-02-01
CN106432225B (zh) 2019-02-19
ES2546635T3 (es) 2015-09-25
IL239997A0 (en) 2015-08-31
EP2719699A1 (en) 2014-04-16
US20200179377A1 (en) 2020-06-11
CN102906092A (zh) 2013-01-30
CY1123777T1 (el) 2022-03-24
EP3511330B1 (en) 2020-09-30
KR101434766B1 (ko) 2014-08-26
CA2785749A1 (en) 2011-07-07
EP2966075B1 (en) 2019-02-27
KR20170098324A (ko) 2017-08-29
BR112012016129B1 (pt) 2020-11-03
EP2519524A1 (en) 2012-11-07
US20120264739A1 (en) 2012-10-18
AU2015203480B2 (en) 2017-10-26
JP2018009004A (ja) 2018-01-18
PT3795573T (pt) 2022-09-15
HUE052828T2 (hu) 2021-05-28
US20150368271A1 (en) 2015-12-24
DK3511330T3 (da) 2020-12-21
EP2519524A4 (en) 2013-07-03
HUE059696T2 (hu) 2022-12-28
CN102906092B (zh) 2016-08-03
AU2010338712B2 (en) 2015-04-02
US9956218B2 (en) 2018-05-01
EP3795573B1 (en) 2022-07-06
AU2015203480A1 (en) 2015-07-16
IL220433B (en) 2018-01-31
LT3795573T (lt) 2022-11-10
HRP20150952T1 (hr) 2015-10-09
SI2719699T1 (sl) 2015-12-31
HRP20221090T1 (hr) 2022-11-25
WO2011079804A1 (en) 2011-07-07
US20120245178A1 (en) 2012-09-27
ZA201205730B (en) 2016-01-27
KR101771299B1 (ko) 2017-08-24
HK1194071A1 (en) 2014-10-10
AU2010338712A1 (en) 2012-07-12
CU20120101A7 (es) 2012-10-15
PL3795573T3 (pl) 2022-11-21
US8507487B2 (en) 2013-08-13
MX336996B (es) 2016-02-09
MX2012007756A (es) 2012-11-06
HRP20202017T1 (hr) 2021-02-19
KR20140059307A (ko) 2014-05-15
GT201200220A (es) 2014-12-22
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
ECSP12012011A (es) 2012-10-30
CL2012001752A1 (es) 2013-01-25
JP2016155848A (ja) 2016-09-01
KR101905350B1 (ko) 2018-11-30
DK2719699T3 (en) 2015-08-24
IL239997A (en) 2017-11-30
RS54217B1 (en) 2015-12-31
EP3511330A1 (en) 2019-07-17
SI3511330T1 (sl) 2021-01-29
US10946014B2 (en) 2021-03-16
PT2719699E (pt) 2015-09-30
ES2726152T3 (es) 2019-10-02
EA025466B1 (ru) 2016-12-30
EP3795573A1 (en) 2021-03-24
JP6486999B2 (ja) 2019-03-20
RS61281B1 (sr) 2021-02-26
CU24167B1 (es) 2016-03-31
HK1216880A1 (zh) 2016-12-09
NZ601128A (en) 2014-12-24
EA201200951A1 (ru) 2013-09-30
PE20160588A1 (es) 2016-07-09
US20180263977A1 (en) 2018-09-20
EA201691461A1 (ru) 2017-01-30
CN106117248B (zh) 2019-01-22
US20170027934A1 (en) 2017-02-02
RS63612B1 (sr) 2022-10-31
JP2019108345A (ja) 2019-07-04
US20210154192A1 (en) 2021-05-27
DK3795573T3 (da) 2022-09-19
SG181781A1 (en) 2012-07-30
EP2719699B1 (en) 2015-07-08
US8987269B2 (en) 2015-03-24
EP2966075A1 (en) 2016-01-13
JP2013209418A (ja) 2013-10-10
CN106432225A (zh) 2017-02-22
JP2013516393A (ja) 2013-05-13
JP5337313B2 (ja) 2013-11-06
CN106117248A (zh) 2016-11-16
US11896592B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
US10946014B2 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor